Ayahuasca vs Psilocybin: A Practitioner's Retreat Comparison

The choice between an ayahuasca retreat and a psilocybin retreat is one of the most common questions clients arrive with, and the honest answer is that they are not the same intervention with different scenery. The duration is different. The body load is different. The subjective texture is different. The integration demands are different. And the legal and cost picture is different. Treating them as substitutable is the first mistake that leads people to book the wrong retreat.

I have sat with ayahuasca in Ecuador and psilocybin in Mexico across multiple programs, and I have worked with over 200 post-retreat clients who came back from one substance or the other looking for integration help. The pattern that recurs is clean. People who chose ayahuasca because they wanted "the strongest experience" sometimes arrive overwhelmed and dysregulated for months. People who chose psilocybin because they wanted "the gentler one" sometimes report that the session was deceptively quiet and the insights took weeks to land. Both are valid. They are valid for different reasons, and the matching matters more than the strength.

This piece walks through the practical comparison axes, with the research evidence where it exists, and a framework for matching the substance to the person rather than the marketing. It is written for someone with a retreat decision in front of them in the next 90 days, not for a literature review.

How Do Ayahuasca and Psilocybin Compare Side by Side?

The cleanest way to see the comparison is to put the practical axes next to each other in one table. Both substances act through serotonergic mechanisms, both produce substantial antidepressant signals in clinical trials, and both run roughly 4 to 8 hours acute, but the similarities end there. The table below summarizes the eight comparison axes that actually matter when you are choosing a retreat, drawn from the published evidence and my experience with retreats on both sides.

The table tells you the shape of the choice. It does not tell you which one is right for you. That depends on what you can tolerate physically, what kind of work you are doing psychologically, and what your access and budget actually permit. The rest of this piece unpacks each axis with the evidence behind it.

What Are Ayahuasca and Psilocybin, Pharmacologically?

The two substances share the serotonin family but differ structurally. Ayahuasca is a brewed combination of two plants: Banisteriopsis caapi vine and Psychotria viridis leaf, providing harmine and harmaline (MAOIs) plus N,N-DMT. The MAOIs are what make oral DMT active. Psilocybin is a single naturally occurring tryptamine found in roughly 200 species of mushrooms, metabolized in the body to psilocin, the active compound. The 2018 dos Santos et al. review in Neuroscience and Biobehavioral Reviews maps both compound classes against their clinical evidence base.

The MAOI component of ayahuasca is what produces both the duration and the dietary requirements. By inhibiting monoamine oxidase, the brew allows orally ingested DMT to reach the brain, and it also temporarily prevents the body from breaking down dietary tyramine and certain medications. This is why ayahuasca retreats enforce a 2 to 4 week dieta restricting aged cheese, cured meats, alcohol, and most psychiatric medications including SSRIs, SNRIs, and tricyclic antidepressants. The interaction with serotonergic medications can produce serotonin syndrome.

Psilocybin pharmacology is more straightforward. Oral psilocybin is dephosphorylated to psilocin, which acts primarily as a 5-HT2A receptor agonist. Onset is 20 to 60 minutes, peak at 90 to 180 minutes, return to baseline by 4 to 6 hours. There is no MAOI component and no extended dietary restriction. The SSRI question for psilocybin is about effect blunting, not safety, as covered in the SSRI interaction guide on this site.

Why the MAOI Difference Matters Practically

The MAOI piece sounds technical, but it determines a lot of the lived retreat experience. Ayahuasca requires you to overhaul your diet, often discontinue medications under physician supervision, and accept a longer and more physiologically demanding session. Psilocybin allows you to walk into the session with much less preparation overhead. For someone with complex medical history or on multiple medications, the prep burden alone can make psilocybin the more accessible choice regardless of which substance feels more aligned philosophically.

How Do the Sessions Differ in Subjective Character?

The subjective contents of an ayahuasca ceremony and a psilocybin session feel like different worlds, even though both substances act at the 5-HT2A receptor. Ayahuasca more often produces vivid visual imagery, narrative sequences, and what people describe as encounters with a teacher presence; psilocybin more often produces emotional and somatic insight with less narrative scaffolding. The dos Santos 2018 review documents this character difference across the comparative literature.

The Ecuadorian ceremonies I sat in were structured around the curandero's voice. Icaros, the traditional songs, run continuously through the night, and the imagery comes in waves that often track to the song being sung. There is movement: people sit up, lie down, purge into buckets, return to the mat. The visual content can be intricate, geometric, anthropomorphic. People often report a sense of being shown something, and the question becomes what to do with what they were shown. The session ends with sunrise and a long silent period before group sharing.

The Mexican psilocybin retreats had a quite different texture. Eyeshades, headphones, a curated playlist, a sitter present but quiet. Most people stay in their own field for the bulk of the session. Imagery happens but is often less narrative; more common is direct emotional contact with something the person has been avoiding, or a somatic release that does not need a story attached. The Carhart-Harris 2016 Lancet Psychiatry paper described this contents pattern in early therapeutic trials.

Ayahuasca tends to show people things. Psilocybin tends to let people feel things. The integration work afterwards looks different because the contents are different, and the matching to the person's actual therapeutic need is what the substance choice should follow.

The Visionary vs Internal Distinction

This is not a hard rule. Plenty of people have visual ayahuasca-like experiences on psilocybin, and plenty have quiet internal psilocybin-like experiences on ayahuasca. The distinction is a tendency, and it shapes what each substance is useful for. If your therapeutic question is "what is going on in my marriage that I cannot see," psilocybin's internal-emotional contents may land more directly. If your question is "what does my life want from me now," ayahuasca's narrative-symbolic contents may produce more material to work with.

How Different Is the Body Load Between Them?

The body-load difference is the single most underestimated factor for first-time retreatants. Ayahuasca produces purging in roughly 70 to 90 percent of sessions, often with significant nausea, sweating, cardiovascular activation, and gastrointestinal urgency. Psilocybin produces some nausea in around a third of sessions but rarely purging, and the cardiovascular load is mild. The 2018 dos Santos review and ongoing safety literature both flag this as the largest practical safety difference between the two.

La purga, the ceremonial term for purging, is considered part of the work in the ayahuasca tradition. Practitioners frame it as the release of stuck material, and people often describe it as a relief rather than purely an unpleasant side effect. That said, the physiology is real. The MAOI component plus the DMT plus the cardiovascular activation places real load on the body, and people with heart conditions, uncontrolled hypertension, or eating disorder history are frequently screened out of legitimate retreats. They should be.

Psilocybin does not have this same physical profile. Nausea happens, especially in the first hour, and lemon-tek preparations or empty-stomach protocols try to minimize it. But the heart rate increase is moderate, the GI activation is mild for most people, and the session does not require the same physiological stamina. For someone with chronic GI conditions, anxiety about vomiting, or a body that is already managing a lot, this difference often decides the substance.

What the Dieta Asks of You

The ayahuasca dieta is not optional. Foods high in tyramine, alcohol, and most serotonergic medications need to be cleared for 2 to 4 weeks before the ceremony to avoid hypertensive crisis or serotonin syndrome. Legitimate retreats provide the list and verify compliance during intake. Psilocybin has no equivalent dietary structure beyond an empty stomach the day of. For more on the broader vetting question, the how to vet a psychedelic retreat piece covers what serious screening looks like.

What Does the Research Evidence Say About Each?

The research bases are not symmetrical. Psilocybin has multiple Phase 2b randomized controlled trials and is now in Phase 3 development for treatment-resistant depression; ayahuasca has one small RCT for depression plus a substantial observational literature. Goodwin et al. (2022, NEJM) reported significant MADRS reduction in 233 patients on COMP360 psilocybin 25 mg versus 1 mg control. Carhart-Harris et al. (2016, Lancet Psychiatry) earlier reported 67 percent response at one week in 12 patients with treatment-resistant depression.

For ayahuasca, the foundational randomized trial is Palhano-Fontes et al. (2019, Psychological Medicine), which compared a single ayahuasca dose to placebo in 29 patients with treatment-resistant depression. Response rates were 64 percent in the ayahuasca arm versus 27 percent in placebo at day 7. This is a small but methodologically careful trial, and it represents the rigorous edge of ayahuasca clinical evidence to date. Larger trials are in progress.

The implication for someone choosing a retreat in 2026 is not that one substance "works" and the other does not. Both produce meaningful antidepressant signals across the available evidence. The implication is that the psilocybin evidence base is currently more developed, which has consequences for how clinical teams talk about it, how insurance and regulatory bodies are responding, and how much standardization exists around dose and protocol. The ayahuasca tradition has thousands of years of cultural validation; the clinical research is just earlier in its arc.

What Does Legal Access and Cost Look Like in 2026?

The legal and cost landscape diverged significantly between 2020 and 2026, and the practical retreat options now look quite different by substance. Ayahuasca retains its religious-context legality in Brazil, Peru, Costa Rica, and certain US contexts via the Santo Daime and UDV churches, while psilocybin is now legally accessible through Oregon's licensed service centers and a growing set of retreat jurisdictions. The cost of a 5 to 7 day retreat ranges from roughly $2,000 to $10,000+ depending on substance, location, and the quality of clinical and integration support.

Ayahuasca retreats in Peru and Brazil remain the largest market by volume, with prices typically $2,000 to $5,000 for a 5 to 10 day program. Costa Rica has become a popular intermediate option for clients who want infrastructure closer to North American standards. The legality is built around religious and traditional-medicine frameworks, which means the legal protection extends to the ceremonial context rather than to general use.

Psilocybin retreats have grown most rapidly in Oregon since the 2023 implementation of Measure 109, in the Netherlands using truffles which contain psilocybin and remain legal, and in Jamaica where psilocybin mushrooms are legal. Oregon licensed service centers operate under state regulation with trained facilitators and standardized protocols. Pricing ranges from $3,500 to $10,000+ depending on the program length and the level of medical and integration support. For more on what serious integration looks like after either substance, see psychedelic integration therapy.

Cost Per Session vs Total Cost

The retreat cost is often only part of the picture. Travel, time off work, and proper integration support typically add another $1,500 to $5,000 over the months following the retreat. Skipping integration is the most common false economy, and it is roughly where the gap shows up between retreats that produce durable change and retreats that fade in 60 days. Whichever substance you choose, budget the integration on the front end.

How Does Integration Differ After Ayahuasca vs Psilocybin?

Integration patterns differ because the session contents differ, and the work the practitioner does post-retreat is not interchangeable. Across roughly 200 post-retreat clients I have worked with, ayahuasca integration tends to require translating visionary or archetypal material into present-life relevance, while psilocybin integration tends to require behavioral consolidation of direct emotional insight. Both benefit from 4 to 8 weeks of structured integration after the session.

The ayahuasca client often arrives in integration with a story. They were shown an animal, a deceased relative, a scene from childhood, a structure of their relationship. The work is meaning-making: what is this material pointing at in your present life, and what does that change about how you act this week. The somatic load of the ceremony itself often also needs stabilization, especially if the dieta was demanding or the purging was intense. The after ayahuasca retreat piece covers the typical 8-week arc in detail.

The psilocybin client often arrives with something quieter. A clear emotional contact, a sense that something shifted, an insight they cannot quite articulate yet. The work is consolidation: what is the behavior change this insight implies, and how do you protect the neuroplasticity window long enough to install it. The contents may take 2 to 4 weeks to fully surface, which surprises people who expected an immediate transformation. The psilocybin therapy preparation guide walks through the front-end of this pathway.

Why Integration Decides Outcome

Both substances produce a neuroplasticity window of roughly 2 to 4 weeks post-session. That window is the time when new associations, new behavior patterns, and new emotional defaults can install with relatively little resistance. Skipping integration during this window is the most common reason retreat effects fade. The window closes whether you use it or not. This is true for ayahuasca and for psilocybin equally; the contents are different, the window is the same.

How Should You Choose Between Ayahuasca and Psilocybin?

The choice between the two substances should be driven by what your nervous system can tolerate, what kind of therapeutic work you are doing, and what your access permits. In my screening for clients planning either retreat type, three questions handle roughly 80 percent of the matching decision: what is the body's current load, what is the therapeutic question, and what does access actually allow.

The first question is about physical and psychological stability. If the client has cardiovascular conditions, eating disorder history, complex GI issues, or is on serotonergic medications that cannot be tapered, ayahuasca is usually contraindicated and psilocybin is more accessible. If the client is on a fluoxetine regimen that needs a 6-week washout regardless of substance, both options require the same lead time, but the post-session physical recovery is easier with psilocybin.

The second question is about what you are actually working on. People who are looking for explicit teaching, narrative material, or a sense of being shown something often resonate with ayahuasca. People who are looking for direct contact with an emotion they have been avoiding, or for somatic insight without a story attached, often resonate with psilocybin. Neither is more profound; they produce different kinds of material to work with afterward.

The third question is about real-world access. Legal psilocybin retreats are now operating under regulated frameworks in Oregon, the Netherlands, and Jamaica. Legal ayahuasca remains tied to religious and traditional contexts in South America and certain US religious organizations. Travel feasibility, dietary tolerance for the dieta, and budget all factor in. The point is not to gatekeep but to make the decision deliberately. Both can produce excellent work when matched well.

The Direct Access Method screens for substance choice during intake because the integration protocols are different and the matching matters. The single most common preventable failure mode I see is someone choosing the more famous or more dramatic-sounding retreat without actually mapping it to their body, their question, or their integration capacity. The remedy is slow: clarify the question first, then choose the substance, then choose the retreat. Not the other way around.

Frequently Asked Questions About Ayahuasca vs Psilocybin